BRAINSTORM CELL THERAPEUTICS INC. Grants Receivable
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) had Grants Receivable of $15.91 million as of 2017-07-31, per its 10-Q filed 2019-11-14.
Discontinued › Notes › Nontrade Receivables
us-gaap:GrantsReceivable · last filed 2019-11-14
- 2017-07-31: Grants Receivable $15.91M.
| Period end | Grants Receivable |
|---|---|
| 2017-07-31 | $15.91M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |